Denmark-based Evosep, the bioscience company that claims to be leading the standardization of proteomics for clinical use, announced that it has raised €37.48M in a fresh round of funding.
Evosep aims to improve quality of life and patient care by innovating how protein-based clinical diagnostics are performed.
The investment came from Novo Holdings, an international life science investor. Denmark’s Export & Investment Fund Evosep’s existing investors also participated.
The company was founded in 2016 by proteomics technology pioneer Ole Vorm and some of Evosep’s senior leaders, who all have a long history of working together in the field of liquid chromatography-mass spectrometry (LC-MS).
According to Evosep, the team has commercialized a ‘best-in-class’ liquid chromatography platform that has been received well by both the scientific community and the pharmaceutical industry.
Evosep says that the funds will help them promote clinical proteomics applications made possible by its standardized liquid chromatography technology.
Additionally, the funds will also enable the company to further expand its footprint globally, particularly in the US market, offering additional clients a solution for reliable, high-throughput proteomics.
Read more on Tech Gist Africa:
Danish startup OKTO GRID bags €3M
